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Decreased serum zinc is an effect of ageing and
not Alzheimer’s disease†
Alan Rembach,‡a Dominic J. Hare,‡ab James D. Doecke,cd Samantha C. Burnham,c
Irene Volitakis,a Christopher J. Fowler,a Robert A. Cherny,a Catriona McLean,e
Rudolf Grimm,f Ralph Martins,g David Ames,h Colin L. Masters,a Ashley I. Busha and
Blaine R. Roberts*a
We examined the distribution of zinc in the periphery (erythrocytes
and serum) in a large, well-characterised cohort, the Australian
Imaging, Biomarkers and Lifestyle (AIBL) study, in order to determine
if there is systemic perturbation in zinc homeostasis in Alzheimer’s
disease (AD). We observed an age dependent decrease in serum zinc
of approximately 0.4% per year. When correcting for the age depen-
dent decline in serum zinc no significant difference between healthy
controls (HC), mildly cognitively impaired (MCI) or AD subjects was
observed.
Alzheimer’s disease (AD) is the most prevalent cause of demen-
tia in the aged community, and is a progressive and chronic
neurodegeneration that is expected to afflict over 115 million
individuals worldwide by 2050 if effective disease modifying
treatments are not identified.1 AD is characterised by the
accumulation of aggregated amyloid beta (Ab) in extracellular
plaques and neuronal tangles of phosphorylated tau,2 yet
despite considerable knowledge concerning the underlying
processes in AD, the precise toxic principal of this disorder
has yet to be identified.
The concept of a loss of metallostasis,3 or a disturbance in
metal homeostasis, has recently been proposed as a key element
in the pathway leading to Ab toxicity and AD.4–8 In particular,
zinc has been the focus of intense research for its critical role in
synaptic maintenance and neuronal transmission.9,10 In the
brain, zinc is a redox-inert but essential biological metal involved
in a range of catalytic activities11 and is implicated in AD for its
role in amyloid precursor protein transcription,12–14 and in
inducing soluble Ab to aggregate and precipitate.15–18 Levels
of peripheral zinc have been studied as putative disease bio-
markers, though inconsistencies have emerged indicating that
serum or plasma zinc may not reflect changes occurring in the
central nervous system (CNS). A number of conflicting studies
have shown a significant increase,19 a significant decrease,20–23
or no differences24,25 in peripheral zinc in AD when compared
to healthy subjects. Furthermore, studies of the zinc concen-
tration in cerebral spinal fluid (CSF) have produced varying
results indicating either a decrease in CSF zinc in AD26 or no
significant difference from control groups.27,28 Even within the
AD brain itself, reported changes to total zinc levels are incon-
sistent,29,30 with decreased zinc reported in certain brain
regions,31,32 contrasting an increase observed in other areas,33–36
These inconsistencies are most likely due to low statistical power
from a limited number of samples.
AIBL is a unique resource of over 1000 enrolled AD, MCI and
HCs. It is a longitudinal, prospective and multidisciplinary
study that compares clinically characterised participants with
amyloid imaging modalities,37 providing significant power to
fully assess peripheral zinc status in a large, well-characterised
AD cohort. Thus, the aim of this study was to examine the
distribution of zinc in the periphery (erythrocytes and serum) in
the AIBL study to determine if there is systemic perturbation in
zinc homeostasis measurable in blood.
Serum zinc concentration was measured in the baseline AIBL
cohort of 1084 subjects (complete, less 28 samples of the total
1112, which were deemed unsuitable for analysis). Comprehensive
demographics, including age, sex, apolipoprotein-E type 4 (ApoEe4)
allele status, Clinical Dementia Rating Scale Sum of Boxes score
(CDR SOB; used to stage dementia) and mini-mental state
examination (MMSE) questionnaire score are presented in
Table 1. In the AIBL cohort, the HC group are significantly
younger than the AD group ( po 0.0001), and contain a smaller
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number of ApoEe4 carriers ( po 0.0001). As expected, CDR SOB
and MMSE score are consistently and significantly lower in
the AD cohort ( p o 0.0001). There was no difference in the
proportion of males to females between the clinical classifica-
tion groups ( p = 0.335).
Analytical validity of our ICP-MS zinc assay was tested
against a commercial standard serum (Seronormt) and spike
recovery from a characterised serum standard (Table S1, ESI†).
1084 individual serum samples were analysed over a 6-day
period. Recovery of zinc from Seronormt standards was mea-
sured twice daily and was consistently within 10% of certified
values. Similarly, spiked serum displayed good precision and
accuracy in daily quality control checks. Twenty-five individual
calibrations were performed, with acceptable background equiva-
lent concentration (0.892  0.65 mg L1) and detection limits
(0.511  0.871 mg L1) and linearity (R24 0.999) over the analysis
period.
Serum zinc concentrations were subdivided according
to clinical classification, sex and ApoEe4 allele distribution
(Table 2). There was a subtle decrease in zinc concentration
in AD subjects when compared to HCs (HC 12.730  2.489 mM vs.
AD 12.206  2.808 mM). ANOVA of the marginal means across all
three clinical groups showed a significant decrease in serum zinc
levels ( p = 0.003). Comparisons showed that this difference was
driven by the HC vs. AD group difference ( p = 0.001), with the
HC-MCI group comparison not significantly different ( p = 0.679).
Independent of clinical classification we observed a small
but significant decrease in serum zinc with age (Fig. 1a; see
Fig. S1 (ESI†) for serum zinc levels in each classification), equating
to a 0.051  0.042 mM per year decrease in the AIBL cohort, or
0.40  0.33% per year of mean serum zinc concentration. In AIBL,
where AD subjects are, on average, 8.2 years older than their
HC counterparts, this decrease in serum zinc with age represents a
0.418  0.344 mM disparity between the two cohorts, which likely
accounts for the 0.524 mMdifference in serum zinc observed. Thus,
when correcting for age as a covariate in the AIBL population,38 the
previously observed decrease in serum zinc was abolished.
Unlike previous reports,39 we did not observe a significant
difference in serum zinc concentration according to sex (Fig. 1b).
Serum zinc levels did appear lower in AD females as compared
with AD males, however this did not reach statistical significance
(female AD 11.910  2.413 mM vs. male AD 12.706  3.332 mM;
p = 0.073). ANOVA of serum zinc levels according to ApoE allele
status was also unchanged (Fig. 1c). As ApoEe4 carriers have
increased risk of developing AD,40 we also examined the
influence of ApoE allele status in each clinical classification.
No statistically significant difference was observed between
classes or within each classification (Table S2, ESI†), though
there was a decreasing trend in ApoEe4 carriers across the three
clinical classifications. Similarly, in a pilot study AD and HC
participants (n = 40 per group) showed no significant difference
in erythrocyte zinc concentration (Fig. 1d).
Table 1 Serum zinc cohort demographics. ApoEe4 refers to the number
of subjects with at least 1 apolipoprotein e4 allele. CDR SOB is the Clinical
Dementia Rating Scale Sum of Boxes score used to stage dementia. MMSE
is the mini-mental state examination questionnaire score. Figures in
parentheses are 1 standard deviation
Classification HC MCI AD p-value
N 753 126 205
Age, years 70.6 (7) 76.2 (7.6) 78.8 (8.6) o0.001
Sex, n female 434 72 127 0.335
ApoEe4 205 63 128 o0.001
CDR SOB 0.0 (0.1) 1.2 (0.8) 5.8 (2.9) o0.001
MMSE 28.9 (1.2) 26.2 (2.7) 18.9 (5.3) o0.001
Table 2 Serum zinc concentration by classification, sex and ApoEe4 allele status, and significance before and after correction for age, sex and ApoEe4
status. Figures in parentheses are 1 standard deviation. Adjusted p-value represents significance after correction for age as a type I error
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Baseline all (n = 1084) 12.73 (2.489) 12.604 (2.082) 12.206 (2.808) 0.003 0.689 0.679 0.544 0.001 0.679
Baseline males (n = 451) 12.671 (2.178) 12.76 (2.194) 12.706 (3.332) 0.896 0.230 0.758 0.469 0.747 0.223
Baseline females (n = 633) 12.774 (2.701) 12.491 (2.006) 11.91 (2.413) o0.001 0.195 0.436 0.741 o0.001 0.177
ApoEe4 (+) (n = 396) 12.919 (2.516) 12.454 (1.925) 12.013 (2.336) o0.001 0.053 0.166 0.762 o0.001 0.137
ApoEe4 () (n = 688) 12.658 (2.477) 12.763 (2.244) 12.524 (3.446) 0.590 0.236 0.673 0.244 0.346 0.419
Fig. 1 (a) Serum zinc decreases with age and is (b) consistent between
sex, (c) ApoE allele status (n in parentheses) and (d) not significantly






















































































1218 | Metallomics, 2014, 6, 1216--1219 This journal is©The Royal Society of Chemistry 2014
Understanding that subtle changes in serum zinc may not
be reflected in bulk analysis, we used size exclusion inductively
coupled plasma mass spectrometry (SEC-ICP-MS)41 to profile
the zinc binding species present in plasma according to mole-
cular size of protein species. Using SEC-ICP-MS we compared the
zinc profile of 38 HC and 38 AD age and sex matched subjects.
Reflecting the total serum zinc results, we observed no signifi-
cant difference in zinc levels attributable to zinc-binding pro-
teins in either clinical group (Fig. 2) ( p 4 0.05).
Peripheral zinc levels are highly regulated and are under the
influence of homeostatic and environmental parameters such
as diet or the concentration of other metals, including copper,
and it is assumed that zinc homeostasis is compromised during
the aging processes. In AIBL, the Cu/Zn ratio was slightly higher
in the AD cohort (HC = 0.824; MCI = 0.806; AD = 0.798; p = 0.085)
though again this was attributed to effects of age, as has been
shown by others.42
We propose that previously reported decreases in serum zinc
concentration may be attributed to either small data sets with
low statistical power,20,21 or an effect of decreased zinc in the
typically older AD population.22,23 The size of the AIBL study
permits detailed study into the effects of age on serum zinc
levels, which we found decreases inline with age. This does not,
however, suggest that zinc is not implicated in AD pathology in
the brain, where zinc enrichment in amyloid pathology is a
robust feature of the disease.29,30,43 Regardless, we conclude that
it is unlikely variations in zinc concentration due to changes in
CNS metallostasis in AD can be detected in the periphery with-
out the covariate influence of ageing masking subtle changes
that are independent of disease.
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